- The disease
- Mucopolysaccharidosis (MPS) refers to a group of rare, inherited metabolic conditions in which the body cannot properly break down complex sugar chains called glycosaminoglycans (GAGs). Build-up of GAGs causes progressive damage to multiple organ systems, including bones, joints, the heart, and in some subtypes, the brain. The four subtypes targeted here — MPS I (Hurler/Scheie), MPS II (Hunter), MPS III (Sanfilippo), and MPS IVA (Morquio A) — each result from a deficiency in a specific enzyme responsible for GAG degradation. These are lifelong, often severely debilitating conditions with limited approved treatment options, particularly for the neurological features seen in some subtypes.
- What the asset is trying to do
- The active drug in iPPS is pentosan polysulfate sodium (PPS), a semi-synthetic sulfated polysaccharide. Based on the registered trial interventions (per ClinicalTrials.gov NCT06917404), iPPS is administered by subcutaneous injection. The precise molecular target of PPS in MPS is listed as unknown in this asset's profile, and no mechanism-of-action detail has been filed by the company in the data available.
- What the trial is measuring, and why it matters
- The pivotal Phase 3 trial registered under NCT06917404 is evaluating PPS against placebo in patients with MPS Types I, II, III, and IVA (per ClinicalTrials.gov NCT06917404). The specific primary and secondary endpoints for this MPS trial are not described in the registry record available for this brief.
- Efficacy benchmarks in this setting
- Approved therapies in MPS subtypes include enzyme replacement therapies (ERTs) such as laronidase for MPS I (per the laronidase US prescribing information) and idursulfase for MPS II (per the idursulfase US prescribing information); hematopoietic stem cell transplant is also used in selected MPS I patients. Specific efficacy benchmarks — such as urinary GAG reduction and six-minute walk test outcomes — have been reported for these approved agents in their respective registrational studies. Any efficacy figures from early-stage PPS studies in MPS are not statistically comparable to data from approved therapies studied in different populations under different protocols.
- Commercial context
- Several MPS subtypes have at least one approved therapy in major markets: MPS I and MPS II each have approved ERTs in the US and EU (per FDA and EMA approval records). MPS III (Sanfilippo syndrome) has no approved disease-modifying therapy in the US or EU as of the data available. MPS IVA has an approved ERT, elosulfase alfa, in the US (per FDA approval records). Paradigm Biopharmaceuticals lists iPPS (PPS) as its lead asset, and the company completed enrolment in this pivotal Phase 3 study as announced on 18 June 2026 (per ASX announcement dated 14 June 2026). No licensing deals, manufacturing partnerships, or deal comparables specific to this asset have been disclosed in the announcements available.